Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2-18
SponsorRenJi Hospital
About this trial
Liver transplantation in children is highly successful with \>80% having 20 years survival. Most pediatric liver diseases are potentially curable with liver transplantation and it is important to establish whether children who have undergone successful transplantation can expect a normal life expectancy or whether there will be a gradual decline in liver function and eventual graft loss. The most common reasons in late graft loss in children are unexplained graft inflammation ("idiopathic" post-transplant hepatitis) and graft fibrosis. PRO-C3, a disintegrin and metalloproteinase with thrombospondin motifs-generated neo-epitope marker of type III collagen formation, has been proved to be a marker of fibrosis in patients with NAFLD. The aim of this study is to explore the role of Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA) in children received liver transplantation.
Eligibility criteria
Qualifiers
Male or female participant must be between 8 weeks and 18 years of age.
Participant is a recipient of a first liver allograft from cadaveric or living donors.
Participant is a single-organ recipient (liver only).
Participants' parent/guardian is capable of understanding the purposes and risks of the study and must sign an informed consent for the study.
Disqualifiers
Participants older than 18 years of age
Pregnant or breastfeeding
Active systemic infections
Receiving any form of solid organ retransplantation
Trial design
Treatments tested in this trial
- Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)
Treatment groups
1,200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov